Missing Information

Introduction

Missing Information is one of the three categories of safety concerns used within the Safety Specification of a Risk Management Plan (RMP).

Unlike Important Identified Risks and Important Potential Risks, Missing Information does not describe a specific adverse event or safety outcome. Instead, it describes a meaningful gap in knowledge that may affect understanding of the product's safety profile or benefit–risk balance, and that therefore requires active consideration within the pharmacovigilance and risk-management framework.

Historically, RMPs often contained extensive lists of populations with limited clinical experience. Modern regulatory practice has moved toward a more focused approach: the mere existence of limited data is not sufficient to justify inclusion as Missing Information. The key test is whether the lack of information creates uncertainty that is important for risk management or decision making.

This article explains the regulatory concept and practical implementation of Missing Information, describes governance and inspection expectations, and provides pragmatic tools to improve the quality and utility of Missing Information entries in RMPs.

Regulatory Concept

Missing Information refers to:

Gaps in knowledge concerning the safety of a medicinal product for particular patient populations, clinical situations or treatment conditions that are relevant to the product's safety profile or benefit–risk evaluation.

Two elements are required for an item to qualify as Missing Information:

Knowledge Gap
        +
Risk Management Importance
        =
Missing Information

Both elements are necessary. A simple absence of data is not enough; the uncertainty must have potential implications for clinical use, regulatory decisions, or the need for targeted post-authorisation activities.

Regulatory references and context

• EMA: GVP Module V — Risk Management Systems (core guidance on Safety Specification categories and lifecycle management) [1].
• EMA: RMP template and supporting guidance (format and content expectations) [2].
• EU legislation: Commission Implementing Regulation (EU) No 520/2012 (procedural requirements for pharmacovigilance systems) [3].
• ICH: E2E Pharmacovigilance Planning (framework for post-authorisation safety activities) [4].
• For non-EU territories: national/regional guidance (e.g., FDA guidance on postmarketing requirements and REMS) should be considered; concepts are similar but terminology and regulatory instruments differ [7].

Why Missing Information Exists

At authorisation, clinical development programmes cannot cover every condition of real-world use. Common practical limitations include:

• Restricted inclusion/exclusion criteria in trials
• Limited age ranges or frailty representation
• Short treatment durations relative to intended real-world use
• Small sample sizes in subgroups of interest
• Exclusion of patients with severe organ impairment or comorbidities
• Limited pregnancy/lactation exposure
• Sparse data in ethnic groups or geographic regions where use is expected

These limitations create uncertainty. The Missing Information category exists to capture those uncertainties that are relevant to safety and that potentially require targeted surveillance, study or risk minimisation efforts.

Missing Information Versus Lack of Data

Not all absence of data constitutes Missing Information.

A candidate gap should be assessed against a structured set of questions (see Practical Implementation below). For example, the statement "No clinical trial participants older than 92 years" is data absence; it becomes Missing Information only if treating patients >92 is anticipated and the lack of data creates uncertainty that could affect benefit–risk decisions or patient management.

Key decision threshold: would resolving the gap change clinical recommendations, labeling, monitoring requirements, or trigger additional regulatory action? If yes, it is likely Missing Information.

Why Modern RMPs Contain Fewer Missing Information Categories

Regulatory practice emphasises proportionate, evidence-based RMPs. Current expectations focus on:

• Clinical relevance: is the gap significant for product use?
• Safety impact: could the uncertainty materially affect benefit–risk?
• Actionability: can pharmacovigilance or risk-minimisation activities reasonably reduce the uncertainty?

This shift reduces unnecessary or generic listings (e.g., "elderly", "pregnancy") unless supported by product-specific rationale.

Common Categories of Missing Information

Typical categories that may qualify (product-dependent):

• Pregnancy exposure and outcomes (including teratogenicity and neonatal effects)
• Breastfeeding exposure (infant safety and exposure levels)
• Long-term use (toxicity emerging only after prolonged exposure)
• Severe hepatic or renal impairment
• Paediatric populations (when paediatric use is expected or plausible)
• Use in frail, multimorbid, or polypharmacy populations
• Use during concomitant therapy with specific interacting agents
• Rare but clinically important subgroups (e.g., genetic polymorphisms)
• Use in certain surgical settings or with specific procedures
• Immunogenicity-related uncertainty for biologics

Each entry must be justified with an explanation of why the gap matters, what is known, and what will be done to reduce the uncertainty.

Relationship to Important Potential and Identified Risks

Clarifying distinctions

• Important Identified Risk: a causal association between the medicinal product and an adverse outcome is established or considered likely. Example: anaphylaxis.
• Important Potential Risk: a plausible but unconfirmed association exists for a specific adverse outcome. Example: potential severe hepatotoxicity suspected from class effect or preclinical signal.
• Missing Information: a definable knowledge gap regarding safety in a specific population or use condition. Example: limited safety data in severe hepatic impairment.

These categories can coexist. A Missing Information item may later be reclassified to Important Potential or Identified Risk as evidence accrues.

How Missing Information Is Identified (Practical Implementation)

A systematic, multidisciplinary approach improves consistency and defensibility. Suggested steps:

1. Evidence mapping
2. Review clinical trial datasets, CSR appendices and subgroup analyses.
3. Query pharmacovigilance databases for spontaneous reports stratified by age, pregnancy status, organ impairment, etc.

4. Search literature, registries, EHR data, and preclinical toxicology where relevant.

5. Trigger list

6. Predefined triggers in the RMP SOPs (e.g., <300 patient-years in pregnancy; <100 pre-authorisation exposures in a paediatric subgroup; median exposure <6 months when long-term use expected).

7. Structured evaluation

8. Use a checklist or decision tree assessing:

   • Expected real-world use in the subgroup
   • Severity of the treated condition
   • Availability of alternative therapies
   • Plausibility of different safety profile in the subgroup (pharmacokinetics, pharmacodynamics, comorbidity interactions)
   • Whether absence of data could alter label or monitoring
   • Feasibility of obtaining data

9. Cross-functional review

10. Include PV, clinical development, epidemiology, regulatory affairs, and medical affairs in the decision to classify an item as Missing Information.

11. Documentation

12. Record the rationale, data sources, quantitative thresholds, meeting minutes and decision logic in a central repository for inspection.

Practical decision aids - Example quantitative trigger for pregnancy: include as Missing Information if pre-authorisation exposure <300 prospectively followed pregnancies with outcome data, and the drug is likely to be used by women of childbearing potential [1][2]. - Example for renal impairment: include if pharmacokinetic modelling predicts >2-fold exposure change in severe impairment and clinical data in this subgroup are absent.

Justifying Missing Information Entries (Template)

For each proposed Missing Information item, include:

• Title (concise)
• Clear description of the knowledge gap
• Evidence summary (data sources and metrics)
• Clinical relevance (why matters for patient management or benefit–risk)
• Planned or ongoing activities to address the gap (study designs, registries, enhanced surveillance)
• Expected timeline for resolution
• Criteria for removal or reclassification (evidence thresholds)
• Responsible owners and governance body

This template supports robust inspection-ready documentation.

Does Missing Information Require Action?

Not every Missing Information item mandates a formal post-authorisation study. Actions should be proportionate:

• No further action: if the uncertainty is unlikely to change clinical use or benefit–risk and cannot realistically be addressed.
• Routine PV: enhanced signal detection, monitoring of spontaneous reports, targeted analysis.
• Additional PV (PASS, registries): when data can feasibly resolve the gap and will inform labeling or clinical practice [4].
• Risk minimisation: rarely driven solely by missing data; usually reserved when uncertainty has immediate safety implications.

Selection should be justified by feasibility, potential impact and regulatory expectations.

Designing Activities to Address Missing Information

When additional studies are needed, align design with the knowledge gap:

• PASS (non-interventional) for pregnancy outcomes, long-term safety and rare events [4].
• Prospective pregnancy registries with clear inclusion criteria, standardized outcome definitions, comparator groups where possible, and adequate follow-up.
• Disease or product registries that capture relevant confounders for pharmacoepidemiological analysis.
• Long-term extension studies or observational cohorts for chronic exposure.
• Nested case–control or self-controlled case series for rare outcomes.
• Use of real-world data (EHR, claims) with pre-specified analytic plans and sensitivity analyses for confounding.

Operational considerations

• Statistical power and exposure thresholds must be pre-specified.
• Data quality, standardization of case definitions and outcome adjudication are essential.
• Ethical and data privacy requirements must be integrated early.
• Agreements with contract research organisations and data providers should specify access and reporting timelines.

Lifecycle Management and Governance

The RMP Safety Specification is a living document. Effective governance ensures timely review and appropriate changes.

Governance components

• Clear roles and responsibilities:
• QPPV: overall oversight and declaration of system adequacy.
• Head of Safety/Risk Manager: day-to-day management of Missing Information items.
• Benefit–Risk Review Committee or RMP Steering Committee: approves inclusion, reclassification, and removal decisions.
• Clinical/epidemiology leads: provide scientific input and study design oversight.

• Regulatory Affairs: interface with authorities, manage submissions.

• SOPs and workstreams:

• RMP content management SOP describing decision criteria, review intervals and documentation requirements.
• Change control process: for amendments to the Safety Specification and associated action plans.

• Record-keeping policy: storage of rationale, evidence, and meeting minutes in a compliant repository.

• Review cadence:

• Routine, documented reviews at pre-defined intervals (e.g., annually) and ad hoc reviews triggered by material new evidence, regulatory feedback, or safety signals.

• KPIs and metrics:

• Number of active Missing Information items and their average duration
• Percentage with defined resolution plans and timelines
• Time from evidence availability to RMP update
• Completion rates of planned studies and actions
• Inspection findings related to Missing Information

Decision thresholds for removal or reclassification

• Pre-specify measurable thresholds (e.g., number of pregnancies with outcome data, cumulative exposure person-years, statistical bounds excluding a pre-defined risk increase).
• Document the evidence and analytical approach supporting changes.

Escalation and dispute resolution

• Define escalation pathways if cross-functional stakeholders disagree (e.g., chaired committee decision, QPPV final sign-off).
• Maintain audit trail of deliberations and final decisions.

Quality Improvement: General Improvement of Missing Information Practice

A structured improvement programme enhances RMP quality and regulatory confidence. Elements include:

1. Standardised templates and checklists
2. Use a corporate template for Missing Information justification to ensure consistent content and evidence presentation.

3. Include mandatory fields (impact assessment, evidence thresholds, planned activities, owners, timelines).

4. Training and competence

5. Regular training for PV writers, clinical leads and regulatory staff on RMP expectations, EMA GVP Module V, and region-specific requirements [1][2][4].

6. Case-based workshops to apply decision trees and quantitative triggers.

7. Early planning (pre-authorisation)

8. Identify potential Missing Information early during development planning and align studies to mitigate gaps before approval.

9. Incorporate paediatric investigation plans, pregnancy exposure data collection strategies, and dedicated substudies where feasible.

10. Cross-functional review boards

11. Formal RMP or Risk Science Board ensures scientific rigour and consistent decisions across products.

12. Evidence management system

13. Centralised evidence repository linking source data (CSRs, PV extracts, literature) to each Missing Information item for traceability.

14. Version control and searchable meeting minutes for inspection readiness.

15. Metrics and continuous improvement

16. Regular auditing of RMPs against internal standards and regulatory expectations.

17. Root-cause analysis of inspection findings to drive corrective actions and training.

18. Benchmarking and peer review

19. Periodic external review or peer benchmarking to align practice with industry and regulatory best practice.

These initiatives reduce the likelihood of regulatory findings and support robust, defensible RMPs.

Inspection and Audit Considerations (Expanded)

Inspectors expect clear, evidence-based reasoning for each Missing Information item and demonstrable linkage to planned or executed activities. Typical inspection focus areas include:

Documentation and justification

• Clear description of the knowledge gap and why it matters clinically.
• Evidence mapping showing data sources and quantitative metrics.
• Decision-making records: meeting minutes, attendees, options considered, and final rationale.

Linkage to activities

• Traceability from RMP entries to study protocols, registry contracts, PASS plans, and monitoring reports.
• Timelines and milestones for activities to address the gap.

Governance and responsibility

• Roles and responsibilities documented for owners and governance bodies.
• SOPs governing how Missing Information is identified, reviewed and changed.

Data and analyses

• For ongoing activities: interim analyses, enrollment figures, data quality metrics and estimated time to reach thresholds.
• For resolved items: analyses demonstrating the evidence that met pre-specified removal/reclassification criteria.

Change control and archive

• Version history of the Safety Specification and linked documents.
• Rationale for amendments and evidence supporting changes.

Common inspection findings

• Vague or generic justifications that do not explain clinical relevance.
• Lack of measurable criteria for removal or reclassification.
• Missing minutes or incomplete documentation of decision-making.
• Failure to implement or to track planned activities.
• Poor traceability between RMP and study deliverables.

Preparation tips

• Maintain a dossier for each Missing Information item with all supporting documents.
• Ensure the QPPV and key owners understand the rationale and can explain it during interviews.
• Be ready to present interim data for ongoing studies or registries.

Common Regulatory Deficiencies (Consolidated)

Frequent issues that attract regulatory scrutiny include:

• Inclusion of excessive or generic Missing Information categories without product-specific justification.
• Weak or absent clinical relevance statements.
• Lack of measurable endpoints or thresholds for resolution.
• Failure to link Missing Information to concrete activities or study designs.
• Delay in RMP updates after relevant new evidence emerges.
• Poor governance, unclear ownership or absence of documented decision-making.

Addressing these systematically reduces regulatory risk and improves the credibility of the Safety Specification.

Role of the QPPV and Senior Governance

The QPPV is accountable for the pharmacovigilance system and should:

• Understand major areas of Missing Information and the evidence plan to address them.
• Ensure that decisions are evidence-based and appropriately documented.
• Verify that RMP activities are implemented and tracked.
• Serve as an escalation point for disputes or safety-critical decisions.
• Ensure readiness for inspection and provide oversight of corrective actions.

Senior governance (Risk Management Committee, Product Safety Board) must ensure alignment between development, clinical and commercial strategies and risk-management priorities, including allocation of resources to resolve key Missing Information items.

Characteristics of Well-Justified Missing Information

A robust Missing Information entry will:

• Define the knowledge gap precisely and quantitatively where possible.
• Demonstrate clinical relevance to patient safety or benefit–risk.
• Present a clear evidence base and cited data sources.
• Specify an explicit plan to address the gap with timelines and owners.
• Include pre-defined criteria for removal or reclassification.
• Be supported by governance records and version-controlled documentation.

These features facilitate regulatory review and inspection.

Practical Examples (Concise)

Example 1 — Pregnancy exposure - Gap description: Limited human pregnancy exposure; <50 prospectively followed pregnancies. - Relevance: Product likely to be used in women of childbearing potential; animal data show developmental signals. - Planned action: Prospective pregnancy registry with target 300 documented pregnancies and standardized outcome definitions; interim analyses annually. - Removal criteria: Registry completes enrolment and analysis shows no signal of major malformations vs background rates.

Example 2 — Severe renal impairment - Gap description: No data in eGFR <30 mL/min/1.73m²; PK modelling suggests 2.5× exposure. - Relevance: Elderly population with CKD commonly treated for the indication. - Planned action: Dedicated PK/PD study in severe renal impairment with safety follow-up; potential label instruction based on results. - Removal criteria: Study completed and results support either dose adjustment or contraindication.

Key Takeaways

• Missing Information captures safety-relevant knowledge gaps whose resolution matters to benefit–risk assessment or patient management.
• Not all data scarcity equates to Missing Information; inclusion requires a demonstrable link to clinical relevance and actionability.
• Use structured, documented decision-making, measurable criteria for resolution, and robust governance to ensure high-quality RMP content.
• Inspectors expect clear evidence, traceability, and active management of Missing Information items.
• Continuous improvement—through templates, training, cross-functional boards, and metrics—strengthens RMP quality and inspection readiness.

Inspection-ready Supplement: Decision Checklist, Comparative Table and Exemplar RMP Wording

The following supplement is written to be inspection-ready: concise decision aids, a comparative table of Safety Specification categories, and exemplar RMP wording with measurable thresholds and inline regulatory citations. Include these directly in the RMP dossier for each Missing Information item to support regulator queries and inspections.

A. Concise Decision Checklist (inspection-ready)

Use this checklist during the internal review and include the completed checklist in the Missing Information dossier.

• Item title:
• Date of decision:
• Reviewers/attendees (roles):
• Evidence sources reviewed (list CSRs, PV extracts, registries, literature, modelling):
• Quantitative metrics (insert numbers: exposures, person-years, median duration):

Decision path (tick and justify each):

1. Is the subgroup/condition expected in clinical practice? (Yes / No)
2. If Yes, provide evidence of expected use (epidemiology/market data).
3. Does the absence of data create plausible safety uncertainty? (Yes / No)
4. If Yes, describe mechanism/pk/pd rationale.
5. Would resolving the gap plausibly change clinical recommendations, labeling, or monitoring? (Yes / No)
6. Cite potential label text changes or monitoring procedures.
7. Is it feasible to obtain data through PV, PASS, registries or studies within a reasonable timeframe? (Yes / No)
8. If No, document why (ethical/operational constraints).
9. Is the expected benefit of generating data proportionate to cost/complexity? (Yes / No)
10. Recommended classification: (Missing Information / Not Missing Information)
11. Recommended action level (select one):
12. No further action (document rationale)
13. Routine PV (specify additional analyses and frequency)
14. Additional PV (PASS/registry/study) (specify study type, sample size target)
15. Risk minimisation (specify measures)
16. Pre-defined measurable removal/reclassification criteria (specify). Examples:
17. Pregnancy: ≥300 prospectively followed pregnancies with complete outcome data and a comparative analysis excluding a ≥2× increase in major malformations (95% CI upper bound <2.0 for RR) [1][4].
18. Renal impairment: PK study completed (n≥12 for severe impairment) demonstrating exposure increase <2× or dose-adjustment instruction supported by safety data.
19. Long-term use: ≥2,000 cumulative person-years of exposure with prespecified monitoring and no emergent severe safety signal.
20. Timeline to first interim report and final evaluation:
21. Owner and backup owner (name and role):
22. Governance approval (committee name, date, signature):
23. Repository location for supporting documents (link/identifier):

Inspection relevance: store the completed checklist in the RMP dossier for each Missing Information item and ensure the QPPV can present it during an inspection.

B. Comparative Table of Safety Specification Categories

This table is intended for inclusion in the RMP dossier to clarify the difference between categories for inspectors.

Regulatory context: EMA GVP Module V provides central definitions and expectations for each category [1]; the RMP template requires clear categorisation and linkage to planned activities [2].

C. Exemplar RMP Wording with Measurable Thresholds (inspection-ready text blocks)

Below are templated, inspection-ready wording examples for inclusion in the Safety Specification and supporting dossier. Each example includes measurable thresholds, timelines, owners and inline regulatory citations to facilitate regulatory review and inspection.

Note: adapt language for product-specific facts, and populate numeric thresholds with product-specific modelling and operational planning results.

Example A — Pregnancy Exposure (Template wording)

Title: Missing Information — Pregnancy outcomes in women exposed during the first trimester

Description of knowledge gap: - Pre-authorisation exposure: 42 prospectively followed pregnancies with outcome data; insufficient sample size to detect an increased risk of major congenital malformations (MCM) (statistical power <20% to detect RR≥2.0). This constitutes Missing Information because the product will likely be used by women of childbearing potential and preclinical developmental signals (rabbit embryo-fetal toxicity) indicate plausible risk mechanisms [1][2].

Evidence summary: - Clinical trial exposure: 42 prospective pregnancies (outcomes available for 38). - Animal studies: developmental toxicity observed at maternally toxic doses. - Spontaneous reports: 6 pregnancies with incomplete follow-up.

Clinical relevance: - Uncertainty may affect prescriber counselling, contraception recommendations and pregnancy monitoring.

Planned activities: - Prospective pregnancy registry (PASS non-interventional) enrolling pregnant women exposed prospectively; target sample size: 300 prospectively followed pregnancies with complete outcome data. Registry protocol submitted within 3 months of approval; interim analyses annually; final analysis upon attainment of 300 evaluable pregnancies or 5 years, whichever is earlier [4].

Measurable removal/reclassification criteria: - Remove as Missing Information when the registry achieves ≥300 prospectively followed pregnancies with outcome data and the primary analysis yields an upper 95% confidence limit for the relative risk of MCM <2.0 compared to an appropriate external or internal comparator after adjustment for major confounders. If the 95% CI upper bound ≥2.0, consider reclassification to Important Potential Risk and propose additional studies or label measures [1][4].

Owners and governance: - Owner: Head, Pregnancy and Paediatric Safety (name). Backup: Global Head PV. Governance: Annual review by Benefit–Risk Review Committee; QPPV notified and signs off on removal/reclassification decisions.

Inspection notes: - Attach registry protocol, sample size calculation, power assumptions, charter for outcome adjudication committee, data sharing agreement and interim analysis reports.

Regulatory citations: - EMA GVP Module V and RMP template expectations for pregnancy data and PASS [1][2][4].

Example B — Severe Renal Impairment (Template wording)

Title: Missing Information — Safety and appropriate dosing in severe renal impairment (eGFR <30 mL/min/1.73m²)

Description of knowledge gap: - No clinical safety data available in subjects with eGFR <30 mL/min/1.73m². Pharmacokinetic modelling projects a mean increase in AUC of ~2.5-fold in severe impairment, creating uncertainty about dosing and toxicity.

Evidence summary: - PK modelling report (appendix) forecasting 2.5× exposure. - Limited phase II/III data excluded eGFR <45.

Clinical relevance: - Elderly patients with CKD are common in the intended population; higher exposure may increase risk of dose-related adverse events.

Planned activities: - Conduct a dedicated single-dose and multiple-dose PK/PD and safety study in subjects with severe renal impairment (n≥12 per cohort) and matched healthy controls; include safety follow-up for 6 months post-dosing for adverse events of special interest. Study protocol to be finalised within 6 months; first participant in within 12 months.

Measurable removal/reclassification criteria: - If study demonstrates AUC increase <2.0 and no clinically significant safety signal versus matched controls (pre-defined PK and safety endpoints met), then classify as resolved (remove Missing Information) and update SmPC with dosing guidance. If AUC increase ≥2.0 or safety concerns observed, reclassify as Important Potential Risk and propose dose adjustment or contraindication [1][2][4].

Owners and governance: - Owner: Clinical Pharmacology Lead; Sponsor medical monitor; Governance: RMP Steering Committee.

Inspection notes: - Attach PK modelling report, protocol, planned statistical analysis, and timelines.

Regulatory citations: - EMA guidance on study expectations for organ impairment and RMP linkage [1][2].

Example C — Paediatric Use (Template wording)

Title: Missing Information — Safety in paediatric subpopulations (0–2 years; weight <10 kg)

Description of knowledge gap: - No clinical trial data in infants 0–2 years; pharmacodynamics suggest different exposure–response that may alter safety.

Evidence summary: - PIP filed: deferred studies for infants; preclinical juvenile toxicity limited.

Clinical relevance: - Paediatric use anticipated off-label; dosing uncertainty and safety profile unknown.

Planned activities: - Implement a stepwise paediatric development plan (PIP): start with PK bridging in older children, followed by safety cohort studies in 0–2 years as per PIP timetable. Use opportunistic sampling and population PK approaches. Registry data extraction to supplement.

Measurable removal/reclassification criteria: - Removal when studies specified in the PIP are completed and provide sufficient safety and dosing data for 0–2 years (sample size as per PIP), and label is updated accordingly. Alternatively, reclassify to Important Potential Risk if signals emerge.

Owners and governance: - Paediatric lead, with oversight by PIP committee and QPPV.

Inspection notes: - Include PIP, ethical approvals, interim safety reports, and data sharing plans.

Regulatory citations: - ICH E11 (paediatric considerations), EMA PIP and RMP linkage guidance [4][2].

Example D — Long-term Use (Template wording)

Title: Missing Information — Long-term safety (chronic exposure >2 years)

Description of knowledge gap: - Clinical development median exposure 6 months; intended chronic use expected with indefinite duration in some patients.

Evidence summary: - Cumulative pre-authorisation exposure: 7,500 person-months (≈625 person-years).

Clinical relevance: - Long-latency adverse events (e.g., neoplasia, organ toxicity) cannot be excluded.

Planned activities: - Submit protocol for a long-term observational cohort (disease registry or extension study) to capture at least 2,000 cumulative person-years of exposure within 5 years. Pre-specified endpoints: incidence rates for prespecified AESIs, adjudication plan, and methods to handle attrition.

Measurable removal/reclassification criteria: - Remove when 2,000 person-years accumulated with prespecified monitoring and analysis showing no emerging AESI exceeding pre-defined incidence thresholds (e.g., incidence rate ratio upper 95% CI <2 compared with matched comparator). If event signals cross pre-defined thresholds, consider reclassification to Important Potential Risk and implement further studies/risk minimisation [1][4].

Owners and governance: - Epidemiology lead; Safety Board oversight.

Inspection notes: - Provide protocol, power calculations, data sources, and interim surveillance reports.

D. Practical Implementation Details for Measurable Thresholds and Analyses

1. Quantitative thresholds (examples for dossier):
2. Pregnancy: aim for ≥300 prospectively collected pregnancies with complete outcomes; if background incidence of MCM is ~3%, 300 subjects yield sufficient precision to rule out a doubling of risk with reasonable confidence in many settings (use product-specific calculation) [4].
3. Paediatrics: sample sizes aligned to PIP and EMA expectations; where rare outcomes expected, consider registry linkage and case–control nested analyses.
4. Person-years thresholds: for long-term safety, thresholds such as 1,000–2,000 person-years are commonly used as pragmatic targets; justify selection with expected background incidence and power calculations.

5. PK studies: typical minimal per-cohort n=6–12 for PK in special populations, with rationale based on within-subject variability and exposure predictions; larger sample sizes required if safety endpoints are primary.

6. Statistical rules for removal/reclassification:

7. Predefine effect sizes of clinical relevance (e.g., RR≥2.0 for MCM) and the statistical bounds to demonstrate exclusion (e.g., upper 95% CI <2.0).
8. Use sensitivity and subgroup analyses to address confounding in observational data; pre-specify confounder lists and propensity scoring approach.

9. For rare outcomes, plan self-controlled case series or case–control designs to improve efficiency.

10. Interim monitoring and trigger rules:

11. Define stop/go triggers for additional action if interim analysis crosses pre-specified thresholds (e.g., unexpectedly high event rate, enrolment shortfall).

12. Document Data Monitoring Committee charters and interim analysis plans where applicable.

13. Documentation and traceability:

14. Link each threshold and analysis plan to the RMP entry, study protocol, statistical analysis plan (SAP) and governance approvals. Store these in a dossier with version control and accessible audit trail for inspection.

15. Cross-jurisdictional considerations:

16. Where global regulatory obligations differ (e.g., FDA vs EMA), list specific commitments per region and harmonise core metrics where feasible; include references to relevant regional guidance [3][7].

E. Inspection Relevance and Governance for the Supplement

• Keep the supplement as a discrete annex to the Safety Specification for easy retrieval by inspectors. Each Missing Information item should have its own annex containing:
• Completed decision checklist
• Evidence mapping table
• Study/registry protocol(s) or PASS synopsis
• Predefined measurable removal/reclassification criteria and calculation methods
• Governance approvals and meeting minutes
• Interim reports and enrollment status
• Governance expectation: the RMP Steering Committee should review annexes at least annually and certify that thresholds remain appropriate or have been modified with justification; the QPPV should sign-off on each reclassification decision and the dossier should record QPPV rationale and signature.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module V – Risk Management Systems.
2. EMA Risk Management Plan Template.
3. Commission Implementing Regulation (EU) No 520/2012.
4. ICH E2E Pharmacovigilance Planning.
5. EMA Guidance on Safety Concerns and Risk Management Planning.
6. EMA Guideline on Good Pharmacovigilance Practices.
7. FDA Guidance for Industry — Postmarketing Safety Reporting and REMS-related guidance (for cross-jurisdictional context).